Acinetobacter Pneumonia Therapeutics Market Trends

Growth Drivers

• Increasing geriatric population and chronic diseases: The increasingly aging population globally with comorbidities and compromised immune systems puts them at risk of Acinetobacter pneumonia. The elderly population suffering from chronic health diseases result in a higher rate of hospital visits, increasing the risk of exposure to Acinetobacter baumannii. The World Population Prospects reports the population above 65 years of age is growing faster than the population below that and estimates the population above 65 to increase from 10% in 2022 to 16% in 2050.
  
  Aging exacerbates the risk of mortality in Acinetobacter pneumonia, and hence the demand for advanced therapeutic care is on the rise. The demographic shift globally is poised to fuel the growing demand for effective therapeutic solutions.
• Rising prevalence of antibiotic resistant infections: The increasing prevalence of multi-drug resistant (MDR) Acinetobacter baumannii is a major driver of the acinetobacter pneumonia therapeutics market. For instance, in September 2024, research published in the Journal of Global Antimicrobial Resistance estimated an increase in Acinetobacter baumannii pneumonia cases to have increased between 2019 and 2023 along with the rate of carbapenem resistance. Rising cases of MDR A. baumannii have necessitated the demand for new antibiotics and combination therapies to assist the market’s growth.
• Advancements in antimicrobial research: Advancements in antimicrobial research have enabled antibiotic discovery and the development of therapies to target Acinetobacter strains, assisting the robust growth of the acinetobacter pneumonia therapeutics market. Approval of new drugs such as Cefiderocol (Fetroja) is beneficial for the market’s growth as global and local players can invest in the distribution and manufacturing of the drug to cater to the growing demands for therapeutic care. For instance, in February 2024, Taiwan Shionogi & Co., Ltd., announced that Fetroja was approved by the Taiwan Food and Drug Administration (TFDA) for the treatment of hospital acquired pneumonia and other ailments.

Challenges

• High cost of drug development and approval: Developing novel antibiotics for Acinetobacter pneumonia involves considerable investment in research and clinical trials. Additionally, there is no guarantee that the research will be successful, and hence pharmaceutical companies can face challenges allocating funds to research. Moreover, if the efficacy of a therapy is uncertain, then it may not be approved by the regulatory bodies, which can cause uncertain market returns. The time associated with research, clinical trials, approval, and then distribution of new therapeutics can be long, further affecting the market.
• Lack of awareness and delayed diagnosis: The lack of awareness of hospital induced pneumonia, especially in emerging economies with an unreliable health ecosystem, can pose major challenges in treatment. Early identification is vital for treatment and the lack of diagnostic tools or expertise to detect antibiotic-resistance Acinetobacter can stymie the market growth and also dampen chances of expanding to new markets.